COVID-19

SARS-CoV2

Androgenetic Alopecia

Prostate Cancer

Benign Prostatic Hyperplasia

SARS (Severe Acute Respiratory Syndrome)

Dutasteride

Ivermectin

Azithromycin

Proxalutamide

Corpometria Institute

Anti-Androgen Treatment for COVID-19

Percentage of subjects hospitalized due to COVID-19

COVID Ordinal Scale defined as:
Death
Hospitalized on invasive mechanical ventilation or ECMO ( extracorporeal membrane oxygenation)
Hospitalized on non-invasive ventilation or high flow nasal cannula
Hospitalized on supplemental oxygen
Hospitalized not on supplemental oxygen
Not hospitalized with limitation in activity (continued symptoms)
Not hospitalized without limitation in activity (no symptoms)

Symptoms severity of COVID-19 using Brescia-COVID Respiratory Severity Scale (BCRSS)/Algorithm

Applied Biology, Inc.

This study is designed as a prospective, interventional, placebo controlled, double-blinded, randomized parallel assignment study.

Brentuximab Vedotin dose will start at 1.2 mg/kg by intravenous (IV) infusion on Day1 and Day15 plus Cyclophosphamide 500mg/m2 IV on Day1 plus Procarbazine 100mg/m2 by mouth (OR) on Day1 through 5 plus Etoposide 60mg/m2 OR on Day15 through 19 plus Mitoxantrone 6mg/m2 IV on Day15 and Prednisone 30mg/m2 on Day1 through 5 of each 28-day treatment cycles for up to 6 total treatment cycles (approximately 24 weeks or 6 months)

Hodgkin Lymphoma

All patients will be treated with 6 cycles of BV-EPEM

BrentuximabVedotin (BV)

Institut Català d'Oncologia, Hospital Germans Trias i Pujol

Institut Català d'Oncologia, Hospital Duran i Reynals

Hospital Costa del Sol

Hospital Clinic i Provincial de Barcelona

Hospital Vall d'Hebron

Hospital de Basurto

Hospital General Universitario Gregorio Marañon

Hospital Universitario 12 de Octubre

Hospital Universitario La Paz

Hospital Son Llatzer

Hospital Universitario de Salamanca

Hospital Universitario Donostia - Arantzazu

Hospital Universitario Marqués de Valdecilla

Hospital Universitario Virgen del Rocío

Hospital Universitario Miguel Servet

BrEPEM-LH-22017 for Older Patients With Untreated Hodgkin Lymphoma (HL)

A Phase Ib/II Trial of Combined SGN-35 (BrentuximabVedotin) Therapy With Cyclophosphamide, Procarbazine, Prednisone, Etoposide and Mitoxantrone (BrEPEM) for Older Patients With Untreated Hodgkin Lymphoma (HL)

To identify the maximum tolerated dose (MTD) of Brentuximab Vedotin (BV) in combination with EPEM

To assess the percentage of patients with complete response rate after BV-EPEM treatment.

To evaluate the toxicity of the treatment by measure of number of treatment-related adverse events according to CTCAE v4.0

Evaluation of patient without progression of disease

length of time between date of evidence response and progression of disease or death

To evaluate overall response rate (ORR) based on best response (CR and PR) and the tumor local control rate (CR, PR, and stable disease [SD]) with this treatment regimen.

To assess the type, frequency, severity and relationship of adverse events (AEs) to this treatment regimen.

evaluation of patients alive after first dose of treatment and follow up

Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea

Takeda

Phase I: Cycles 1-4 (1 cycle = 28 days) Lenalidomide: 25 mg per day p.o., day 1 to 21 Dexamethasone: 40/20 mg per day p.o., days 1, 8, 15, 22 Nelfinavir: Dose escalation in cohorts of 3 patients
Phase II: Cycles 1-4 (1 cycle = 28 days) Lenalidomide: 25 mg per day p.o., day 1 to 21 Dexamethasone: 40/20 mg per day p.o., days 1, 8, 15, 22 Nelfinavir: Dose established in phase I twice daily p.o., day 1 to 21

Multiple Myeloma

In phase II, the recommended dose of nelfinavir will be administered orally twice daily (in the morning and in the evening) on d1-d21 every 28 days for a maximum of 4 cycles

Nelfinavir

25 mg of lenalidomide (capsules) will be administered orally daily on d1-d21 every 28 days for a maximum of 4 cycles

Lenalidomide

40 mg (for patients <75 years) or 20 mg (for patients ≥75 years) of dexamethasone (tablets) will be administered orally once per day on d1, 8, 15 and 22 every 28 days for a maximum of 4 cycles

Dexamethasone

SAKK - SWISS GROUP FOR CLINICAL CANCER RESEARCH

Istituto Europeo di Oncologia IEO

University of Torino

Kantonsspital Aarau

Kantonsspital Baden

Istituto Oncologico Svizzera Italiana IOSI

Inselspital Bern

Kantonsspital Graubünden

Kantonsspital Olten

Kantonsspital St. Gallen

Regionalspital

UniversitätsSpital Zürich

Nelfinavir and Lenalidomide/Dexamethasone in Progressive Multiple Myeloma

Nelfinavir and Lenalidomide/Dexamethasone in Patients With Progressive Multiple Myeloma That Have Failed Lenalidomide-containing Therapy - A Single Arm Phase I/II Trial

alopecia/protease

Anti-Androgen Treatment for COVID-19

BrEPEM-LH-22017 for Older Patients With Untreated Hodgkin Lymphoma (HL)

Nelfinavir and Lenalidomide/Dexamethasone in Progressive Multiple Myeloma

Najbardziej kompletna baza danych ziół leczniczych poparta naukowo